Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05930886 · ClinicalTrials.gov registry record
Focus Groups in Ethnically and Racially Diverse Families
A clinical trial of Attention Deficit Hyperactivity Disorder and Irritable Mood, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05930886: Recruiting study of Attention Deficit Hyperactivity Disorder and Irritable Mood, sponsored by Oregon Health and Science University.
NCT05930886 is a study of Attention Deficit Hyperactivity Disorder and Irritable Mood that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 30 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05930886, a study of Attention Deficit Hyperactivity Disorder and Irritable Mood, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Focus groups to identify treatment needs and barriers to participation in the planned multinutrient study among racially and ethnically diverse (Black and Hispanic) communities.
Primary Outcome
Purpose is understanding 1. Parents' priorities regarding their child's mental health 2. Facilitators or barriers to research participation generally 3. Parent input on planned study specifically 4. Specific recommendations for modifying the future feasibility study design 5. Previous CIH intervention use
Conditions Studied
Interventions
- OTHER Focus Group
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2025-10-04 |
What NCT05930886 shows while recruiting
NCT05930886 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Focus Group is the first listed.
NCT05930886 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05930886 about?
NCT05930886 is a clinical study titled "Focus Groups in Ethnically and Racially Diverse Families". Focus groups to identify treatment needs and barriers to participation in the planned multinutrient study among racially and ethnically diverse (Black and Hispanic) communities.
What is the current status of trial NCT05930886?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-04-15. Estimated completion is 2025-10-04.
What conditions does trial NCT05930886 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Irritable Mood, Emotional Dysfunction.
What interventions are being tested in trial NCT05930886?
The interventions under investigation include: Focus Group (OTHER).
Who is sponsoring clinical trial NCT05930886?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05930886 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05930886's enrollment target sits among peer trials
30 81st of 102 higher than 14 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Brain, Impulsivity and Compulsivity
RECRUITING
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Exercise in College Students With ADHD
RECRUITING · NA
-
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI